CapitolRadar tracks every publicly disclosed PTGX trade by US congress members and corporate insiders: 0 disclosed trades (0 buys, 0 sells) by 0 tracked traders. Updated daily from official filings.
Want a ping when Congress buys PTGX? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Protagonist Therapeutics, Inc. (PTGX) — Healthcare · Biotechnology, market cap about $8.3B.
CapitolRadar signal history
NEW PICK 2026-09-11
Protagonist Therapeutics CEO and director Dinesh Patel was reported to have bought about $157,059 of PTGX stock. The panel passed mainly because the listed September 10, 2026 trade date is in the future, so the purchase cannot yet be verified as completed. An official Form 4 confirming a valid trade date, price, and open-market purchase would have addressed the main concern.
NEW PICK 2026-09-11
Protagonist Therapeutics President and CEO Dinesh Patel disclosed buying about $1.17 million of PTGX stock. The panel found the large insider purchase notable, but it fell short mainly because Patel has no verified trading history showing his buys outperform SPY. A documented record of prior purchases followed by sustained market-beating returns would have strengthened the case enough to change the verdict.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-…
Frequently asked questions
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.